Incident Chronic Obstructive pulmoNary dIsease Cohort Study (ICONIC)
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jan 31, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ICONIC study is looking into how we can better identify and understand Chronic Obstructive Pulmonary Disease (COPD) in smokers, especially those who may not know they have it. COPD is a serious lung condition often caused by smoking, and many people with it remain undiagnosed. By screening smokers in a general medical setting, the study aims to find out how newly diagnosed patients progress over time and how different types of COPD can affect their treatment and overall health.
To take part in this study, participants must be over 35 years old, have a history of smoking (at least 20 pack-years), and must currently be smoking or have quit less than a month ago. They will also need to provide consent to join the study. Participants who are diagnosed with COPD during the study will be monitored to see how their condition evolves. It’s important to note that people already diagnosed with COPD, those undergoing cancer treatment, pregnant or nursing women, and individuals without social security coverage cannot participate. This study hopes to gather valuable information that could improve the way COPD is managed in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inclusion criteria of smokers with spirometry (pre-inclusion)
- • Age\> 35 years
- • Smoking \> 20 PA
- • Active smoking (cessation \< 1 month)
- • Signature of consent to participate in Phase I of the study
- • Inclusion criteria for patients with incidental COPD
- • FEV1 / FVC \<70% of the theoretical value and / or \<LLN (Lower limit of normal)
- • Signature of consent to participate in Phase II of the study
- Exclusion Criteria:
- • Known COPD
- • Cancer being treated
- • No affiliation to the social security or other social protection scheme
- • Pregnant or lactating woman
- • Patient deprived of liberty or under legal protection (under tutorship or curatorship
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Créteil, Ile De France, France
Patients applied
Trial Officials
Laurent BOYER, MD
Principal Investigator
Assistance Publique Hôpitaux de Paris (AP-HP)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials